hemophilia

The first gene therapy for hemophilia could be approved by the FDA within six months, according to the drugmaker, raising hopes among families. But the drug's price could be $3 million per patient.

The market is flooded with 28 different medications for just 20,000 patients with the hereditary bleeding disorder. Yet intense competition hasn't worked to bring costs down.

A generation that survived life-threatening bleeds, the HIV epidemic and hepatitis C now nears retirement with an illness that can mostly be safely managed at home — for about $250,000 a year.